A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

BackgroundProstate-specific antigen (PSA) is widely used to detect prostate cancer. The low positive predictive value of elevated PSA results in large numbers of unnecessary prostate biopsies. We set out to determine whether a multivariable model including four kallikrein forms (total, free, and intact PSA, and human kallikrein 2 (hK2)) could predict prostate biopsy outcome in previously unscreened men with elevated total PSA.MethodsThe study cohort comprised 740 men in Göteborg, Sweden, undergoing biopsy during the first round of the European Randomized study of Screening for Prostate Cancer. We calculated the area-under-the-curve (AUC) for predicting prostate cancer at biopsy. AUCs for a model including age and PSA (the 'laboratory' model) and age, PSA and digital rectal exam (the 'clinical' model) were compared with those for models that also included additional kallikreins.ResultsAddition of free and intact PSA and hK2 improved AUC from 0.68 to 0.83 and from 0.72 to 0.84, for the laboratory and clinical models respectively. Using a 20% risk of prostate cancer as the threshold for biopsy would have reduced the number of biopsies by 424 (57%) and missed only 31 out of 152 low-grade and 3 out of 40 high-grade cancers.ConclusionMultiple kallikrein forms measured in blood can predict the result of biopsy in previously unscreened men with elevated PSA. A multivariable model can determine which men should be advised to undergo biopsy and which might be advised to continue screening, but defer biopsy until there was stronger evidence of malignancy.

[1]  P. Stattin,et al.  Non‐systematic screening for prostate cancer in SwedenSurvey from the National Prostate Cancer Registry , 2003, Scandinavian journal of urology and nephrology.

[2]  H. Lilja,et al.  Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. , 1995, Clinical chemistry.

[3]  J. Hugosson,et al.  Outcome of Laterally Directed Sextant Biopsies of the Prostate in Screened Males Aged 50–66 Years , 2001, European Urology.

[4]  G. Durkan,et al.  Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol. , 2002, BJU international.

[5]  H. Lilja,et al.  Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. , 2000, Clinical Chemistry.

[6]  J. Oesterling,et al.  In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. , 1996, Urology.

[7]  Jean-Jacques Patard,et al.  Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. , 2007, European urology.

[8]  Freddie C Hamdy,et al.  Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. , 2005, European urology.

[9]  A. Localio,et al.  A meta-analysis of the performance characteristics of the free prostate-specific antigen test. , 2006, Urology.

[10]  J. Beiser,et al.  Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. , 1997, The Journal of urology.

[11]  Hans Lilja,et al.  Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma , 2004, Cancer.

[12]  G. Durkan,et al.  Improving prostate cancer detection with an extended‐core transrectal ultrasonography‐guided prostate biopsy protocol , 2002 .

[13]  J. Hugosson,et al.  Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. , 2001, Clinical chemistry.

[14]  J. Hugosson,et al.  Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. , 2000, Urology.

[15]  H. Ozen,et al.  An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. , 2004, European urology.

[16]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[17]  D. Chan,et al.  Standardization of two immunoassays for human glandular kallikrein 2. , 2003, Clinical chemistry.

[18]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[19]  F. España,et al.  Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. , 1998, Journal of Urology.

[20]  G. Berglund,et al.  Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. , 2006, Clinical chemistry.

[21]  J. Trachtenberg,et al.  Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. G. Blijenberg,et al.  The value of (−7, −5)pro‐prostate‐specific antigen and human kallikrein‐2 as serum markers for grading prostate cancer , 2004, BJU international.

[23]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[24]  I. Thompson,et al.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. , 2006, Journal of the National Cancer Institute.

[25]  Andrew J Vickers,et al.  Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R A Greenes,et al.  Assessment of diagnostic tests when disease verification is subject to selection bias. , 1983, Biometrics.

[27]  H. Lilja,et al.  Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. , 2000, Clinical chemistry.

[28]  S. Loening,et al.  Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .

[30]  A. Haese*,et al.  Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. , 2002, The Journal of urology.

[31]  J. Eastham,et al.  Treatment of chronic prostatitis lowers serum prostate specific antigen. , 2002, The Journal of urology.

[32]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[33]  S. Loening,et al.  A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. , 2005, The Journal of urology.

[34]  H. Lilja,et al.  Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. , 1996, Clinical chemistry.

[35]  W. Catalona,et al.  Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. , 2004, Clinical chemistry.

[36]  H. Lilja,et al.  Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. , 2006, Analytical chemistry.

[37]  Sa A. Wang,et al.  Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens. , 2004, Archives of pathology & laboratory medicine.

[38]  W. Rayford,et al.  Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA) , 2004, Prostate Cancer and Prostatic Diseases.

[39]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[40]  M. Kattan,et al.  Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy , 2007, International journal of cancer.

[41]  A. D'Amico,et al.  Impact of age, benign prostatic hyperplasia, and cancer on prostate‐specific antigen level , 2006, Cancer.

[42]  W. Rayford,et al.  Prostate specific antigen isoforms and human glandular kallikrein 2--which offers the best screening performance in a predominantly black population? , 2006, The Journal of urology.

[43]  Kim Pettersson,et al.  Development of sensitive immunoassays for free and total human glandular kallikrein 2. , 2004, Clinical chemistry.

[44]  Myron Tanncnbaum,et al.  Urologic pathology: The prostate , 1977 .